Scoping out Gastroenterology Start-Ups

The field of gastroenterology is tantalizing for device manufacturers because it offers one of the rare screening paradigms in medicine, and therefore, enormous markets. In the US, it's recommended that everyone over the age of 50 be screened for colorectal cancer by a colonoscopy procedure. However, compliance with colorectal screening recommendations is low, less than 50% for colonoscopy, the gold standard for detecting precancerous polyps. GI endoscopy is unusual among screening paradigms in its degree of invasiveness and cost, and that limits access to screening. Medtech start-ups hope to improve upon this state of affairs by offering new technologies to improve the ease, decrease the discomfort, and increase the efficiency of endoscopic procedures.

When it comes to technological innovation, the field of gastroenterology lags other clinical spaces. Gastroenterologists are said to be slow adopters of new technologies, and disruptive innovation seems to come along only every 30 years or so. The last major advance, say some, happened back in 1983 at DDW (Digestive Disease Week), the annual gastroenterology conference, when Olympus Corp. introduced the first CCD sensing camera on the end of an endoscope, enabling the electronic capture of images. Before that, the last major advance was the advent of fiberoptics in 1956. Those technologies advanced image quality, but the basic endoscopy procedure itself--which relies on snaking a semi-rigid hose at the end of which is a visualization tool through five to six feet of twists and turns in a soft organ--has not changed in 50 years. Start-ups are fond of pointing this out, because, with some rare exceptions, it’s been difficult for all but the largest companies—Olympus, Pentax Corp., Fuji Photo Film Co. Ltd.-- to succeed at capturing any part of the market with new technologies, and indeed, there are many start-up and product failures along the way.

The field is tantalizing because it offers one of the rare screening paradigms in medicine, and therefore, enormous markets. In the US, it’s recommended that everyone over the age of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.